Uterine Carcinosarcoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: UTR024 MIFTS: 58	Uterine Carcinosarcoma Categories: Cancer diseases, Rare diseases, Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Uterine Carcinosarcoma

MalaCards integrated aliases for Uterine Carcinosarcoma:

Name: Uterine Carcinosarcoma ¹¹ ¹⁹ ⁵⁸ ⁵³ ⁵ ¹⁴ ¹⁶ ⁷¹

Carcinosarcoma of the Corpus Uteri ¹⁹ ⁵⁸

Malignant Mixed Müllerian Tumor of the Corpus Uteri ¹⁹

Malignant Mixed Mullerian Tumor of the Corpus Uteri ⁵⁸

Malignant Mixed Müllerian Tumor of Corpus Uteri ¹⁹

Mixed Müllerian Cancer of Corpus Uteri ¹⁹

Mixed Mullerian Cancer of Corpus Uteri ⁵⁸

Mixed Mullerian Sarcoma of Uterus ¹¹

Uterine Corpus Carcinosarcoma ⁷¹

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Malignant neoplasms of female genital organs

Malignant neoplasm of corpus uteri

Malignant neoplasm: Corpus uteri, unspecified

Orphanet: ⁵⁸

Rare gynaecological and obstetric diseases

External Ids:

Disease Ontology ¹¹ DOID:6171

NCIt ⁴⁹ C42700

SNOMED-CT ⁶⁸ 702369008

ICD10 via Orphanet ³² C54.9

Orphanet ⁵⁸ ORPHA213610

EFO ¹⁶ EFO_1000613

UMLS ⁷¹ C0280630 C1704376

Sources

Summaries for Uterine Carcinosarcoma

GARD: ¹⁹ Carcinosarcoma of the corpus uteri is a rare, malignant, mixed epithelial and mesenchymal tumor of the uterine body composed of high-grade carcinomatous and sarcomatous elements. It may present with vaginal bleeding, abnormal vaginal discharge, abdominal pain and/or pelvic mass, with a polypoid tumor sometimes protruding through the cervical canal. Association with Tamoxifen therapy, long-term unopposed estrogen use and previous pelvic radiotherapy has been reported.

MalaCards based summary: Uterine Carcinosarcoma, also known as carcinosarcoma of the corpus uteri, is related to carcinosarcoma and sarcoma, and has symptoms including pelvic pain An important gene associated with Uterine Carcinosarcoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include uterus, ovary and breast, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Decreased viability

Orphanet: ⁵⁸ Carcinosarcoma of the corpus uteri is a rare, malignant, mixed epithelial and mesenchymal tumor of the uterine body composed of high-grade carcinomatous and sarcomatous elements. It may present with vaginal bleeding, abnormal vaginal discharge, abdominal pain and/or pelvic mass, with a polypoid tumor sometimes protruding through the cervical canal. Association with Tamoxifen therapy, long-term unopposed estrogen use and previous pelvic radiotherapy has been reported.

Disease Ontology: ¹¹ A uterine body mixed cancer that has material basis in both endometrial carcinoma and sarcoma.

Sources

Related Diseases for Uterine Carcinosarcoma

Diseases related to Uterine Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 442)

#	Related Disease	Score	Top Affiliating Genes
1	carcinosarcoma	31.6	VIM TP53 PTEN PPP2R1A PIK3CA KIT
2	sarcoma	31.2	VIM TP53 PIK3CA KIT HRAS
3	adenomyosis	30.8	TP53 PTGS2 PTEN
4	endometrial stromal sarcoma	30.8	VIM TP53 KIT H2AC18
5	serous cystadenocarcinoma	30.6	TP53 PTEN PPP2R1A POLE PIK3CA HRAS
6	endometrial cancer	30.5	TP53 PTGS2 PTEN PIK3R1 PIK3CA KIT
7	inherited cancer-predisposing syndrome	30.5	TP53 PTEN POLE KIT EGFR
8	bap1 tumor predisposition syndrome	30.5	TP53 PTEN POLE KIT EGFR
9	endometrial adenocarcinoma	30.4	TP53 PTEN POLE FGFR2 EGFR
10	fallopian tube carcinoma	30.4	TP53 PTEN ERBB2
11	endometrial serous adenocarcinoma	30.4	TP53 PTEN PPP2R1A POLE PIK3CA FBXW7
12	papillary serous adenocarcinoma	30.4	TP53 HRAS ERBB2
13	spindle cell sarcoma	30.4	VIM TP53 KIT
14	rhabdomyosarcoma	30.4	VIM TP53 PTEN PIK3CA LRRC56 KIT
15	large cell neuroendocrine carcinoma	30.4	TP53 HRAS EGFR
16	adenosarcoma	30.4	VIM TP53 KIT ERBB2
17	adenocarcinoma	30.4	TP53 PTGS2 PTEN PIK3CA HRAS FGFR2
18	myoma	30.3	TP53 KIT EGFR
19	chordoma	30.3	VIM TP53 PTEN EGFR
20	angiosarcoma	30.3	VIM KRT8 KIT
21	cervical squamous cell carcinoma	30.2	TP53 PTEN PIK3CA KRT8 FBXW7 EGFR
22	colon adenocarcinoma	30.1	TP53 PTGS2 PIK3CA HRAS FBXW7 EGFR
23	mixed cell type cancer	30.1	TP53 PTEN PPP2R1A POLE PIK3CA KIT
24	myelodysplastic syndrome	29.9	U2AF1 TP53 LRRC56 KIT HRAS H2AC18
25	wilms tumor 1	29.9	U2AF1 TP53 PTEN KIT HRAS H2AC18
26	peripheral nervous system disease	29.8	U2AF1 TP53 PTGS2 PTEN KIT HRAS
27	colonic benign neoplasm	29.7	TP53 PTGS2 PTEN PIK3CA HRAS H2AC18
28	lynch syndrome	29.7	U2AF1 TP53 PTGS2 PTEN PPP2R1A POLE
29	cervical cancer	29.7	U2AF1 TP53 PTGS2 PTEN PIK3CA LRRC56
30	lung cancer	28.8	VIM U2AF1 TP53 PTGS2 PTEN PPP2R1A
31	colorectal cancer	28.8	VIM U2AF1 TP53 PTGS2 PTEN POLE
32	breast cancer	28.7	VIM TP53 PTGS2 PTEN PPP2R1A POLE
33	high-grade astrocytoma	10.5	TP53 PTEN
34	esophagus small cell carcinoma	10.5	PIK3CA ERBB2
35	apocrine adenosis of breast	10.4	TP53 ERBB2
36	testicular gonadoblastoma	10.4	VIM KIT
37	hypoganglionosis	10.4	ERBB3 ERBB2
38	glottis squamous cell carcinoma	10.4	PTEN EGFR
39	breast sarcoma	10.4	TP53 KIT ERBB2
40	lung oat cell carcinoma	10.4	TP53 PTEN PIK3CA
41	breast juvenile papillomatosis	10.4	PTEN PIK3CA ERBB2
42	vulvar sebaceous carcinoma	10.4	TP53 KRT8
43	esophagus verrucous carcinoma	10.4	TP53 PIK3CA EGFR
44	lymphoepithelioma-like thymic carcinoma	10.4	KRT8 KIT
45	verrucous carcinoma	10.4	TP53 PIK3CA EGFR
46	familial ovarian cancer	10.4	TP53 POLE
47	barrett's adenocarcinoma	10.4	TP53 PTGS2 ERBB2
48	good syndrome	10.4	TP53 ERBB2 EGFR
49	idh-wildtype glioblastoma	10.4	TP53 PTEN EGFR
50	uterine sarcoma	10.4

Graphical network of the top 20 diseases related to Uterine Carcinosarcoma:

Sources

Symptoms & Phenotypes for Uterine Carcinosarcoma

UMLS symptoms related to Uterine Carcinosarcoma:

pelvic pain

GenomeRNAi Phenotypes related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

²⁵ (show top 50) (show all 64)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-1	10.85	POLE
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-102	10.85	PIK3R1
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-105	10.85	VIM
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-12	10.85	ERBB3
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	10.85	U2AF1
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-121	10.85	EGFR FBXW7
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-122	10.85	FBXW7
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-123	10.85	POLE
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-136	10.85	U2AF1
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-151	10.85	PTEN
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-152	10.85	KIT
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-153	10.85	U2AF1
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-157	10.85	KIT
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-16	10.85	PTEN
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-161	10.85	ERBB2
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-168	10.85	ERBB2 POLE PTEN
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-170	10.85	KIT
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-177	10.85	PIK3R1 VIM
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-183	10.85	FBXW7
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-189	10.85	VIM
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-196	10.85	HRAS
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-199	10.85	POLE PIK3R1
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-207	10.85	ERBB2 POLE
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-21	10.85	EGFR
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-211	10.85	U2AF1
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-214	10.85	PTEN EGFR PIK3R1
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-28	10.85	HRAS
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-30	10.85	KIT
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-32	10.85	ERBB2 POLE
30	Increased shRNA abundance (Z-score > 2)	GR00366-A-34	10.85	PIK3R1
31	Increased shRNA abundance (Z-score > 2)	GR00366-A-42	10.85	PTEN
32	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	10.85	EGFR PIK3R1
33	Increased shRNA abundance (Z-score > 2)	GR00366-A-52	10.85	FBXW7
34	Increased shRNA abundance (Z-score > 2)	GR00366-A-60	10.85	ERBB2 ERBB3
35	Increased shRNA abundance (Z-score > 2)	GR00366-A-61	10.85	KIT
36	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	10.85	ERBB2 POLE PTEN VIM
37	Increased shRNA abundance (Z-score > 2)	GR00366-A-66	10.85	PTEN
38	Increased shRNA abundance (Z-score > 2)	GR00366-A-82	10.85	H2AC18
39	Increased shRNA abundance (Z-score > 2)	GR00366-A-83	10.85	HRAS
40	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	10.85	ERBB2 POLE EGFR ERBB3 KIT U2AF1
41	Increased shRNA abundance (Z-score > 2)	GR00366-A-87	10.85	ERBB2 HRAS POLE PTEN
42	Increased shRNA abundance (Z-score > 2)	GR00366-A-89	10.85	U2AF1
43	Increased shRNA abundance (Z-score > 2)	GR00366-A-9	10.85	KIT
44	Increased shRNA abundance (Z-score > 2)	GR00366-A-91	10.85	POLE EGFR U2AF1
45	Increased shRNA abundance (Z-score > 2)	GR00366-A-93	10.85	PTEN
46	Increased shRNA abundance (Z-score > 2)	GR00366-A-99	10.85	H2AC18 KIT
47	Decreased viability	GR00055-A-1	10.41	EGFR HRAS PIK3CA
48	Decreased viability	GR00055-A-2	10.41	EGFR HRAS PIK3CA
49	Decreased viability	GR00221-A-1	10.41	EGFR HRAS KIT PIK3CA PIK3R1
50	Decreased viability	GR00221-A-2	10.41	HRAS PIK3CA

MGI Mouse Phenotypes related to Uterine Carcinosarcoma:

⁴⁵ (show all 23)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	10.48	EGFR ERBB2 ERBB3 FBXW7 FGFR2 HRAS
2	homeostasis/metabolism	MP:0005376	10.48	EGFR ERBB2 ERBB3 FBXW7 FGFR2 HRAS
3	nervous system	MP:0003631	10.43	EGFR ERBB2 ERBB3 FBXW7 FGFR2 HRAS
4	normal	MP:0002873	10.41	EGFR ERBB2 ERBB3 FBXW7 FGFR2 HRAS
5	growth/size/body region	MP:0005378	10.41	EGFR ERBB2 ERBB3 FBXW7 FGFR2 HRAS
6	cardiovascular system	MP:0005385	10.39	CHD4 EGFR ERBB2 ERBB3 FBXW7 FGFR2
7	muscle	MP:0005369	10.35	EGFR ERBB2 ERBB3 FGFR2 HRAS KIT
8	endocrine/exocrine gland	MP:0005379	10.34	CHD4 EGFR ERBB2 ERBB3 FBXW7 FGFR2
9	embryo	MP:0005380	10.32	CHD4 EGFR ERBB2 ERBB3 FBXW7 FGFR2
10	immune system	MP:0005387	10.31	CHD4 EGFR ERBB3 FBXW7 FGFR2 KIT
11	cellular	MP:0005384	10.29	CHD4 EGFR ERBB2 ERBB3 FBXW7 FGFR2
12	behavior/neurological	MP:0005386	10.28	CHD4 ERBB2 ERBB3 FGFR2 HRAS KIT
13	digestive/alimentary	MP:0005381	10.27	EGFR ERBB2 ERBB3 FBXW7 FGFR2 HRAS
14	liver/biliary system	MP:0005370	10.22	EGFR FBXW7 FGFR2 KIT KRT8 PIK3R1
15	no phenotypic analysis	MP:0003012	10.19	CHD4 EGFR FGFR2 HRAS KIT PIK3CA
16	pigmentation	MP:0001186	10.16	EGFR ERBB3 FGFR2 KIT PTEN TP53
17	respiratory system	MP:0005388	10.15	EGFR ERBB2 ERBB3 FBXW7 FGFR2 HRAS
18	adipose tissue	MP:0005375	10.1	EGFR FGFR2 PIK3CA PIK3R1 PTEN PTGS2
19	reproductive system	MP:0005389	10.1	EGFR ERBB2 FBXW7 FGFR2 KIT KRT8
20	vision/eye	MP:0005391	10	EGFR FBXW7 FGFR2 KIT PIK3CA PIK3R1
21	hematopoietic system	MP:0005397	10	CHD4 EGFR ERBB2 FBXW7 FGFR2 KIT
22	mortality/aging	MP:0010768	9.93	CHD4 EGFR ERBB2 ERBB3 FBXW7 FGFR2
23	integument	MP:0010771	9.5	EGFR ERBB2 ERBB3 FBXW7 FGFR2 HRAS

Sources

Drugs & Therapeutics for Uterine Carcinosarcoma

Drugs for Uterine Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Carboplatin

Approved

Phase 2, Phase 3

41575-94-4

10339178 38904

Paclitaxel

Approved, Vet_approved

Phase 2, Phase 3

33069-62-4

36314

Pertuzumab

Approved

Phase 2, Phase 3

380610-27-5

Trastuzumab

Approved, Investigational

Phase 2, Phase 3

180288-69-1

Cyclophosphamide

Approved, Investigational

Phase 3

50-18-0, 6055-19-2

2907

Ifosfamide

Approved

Phase 3

3778-73-2

3690

Mechlorethamine

Approved, Investigational

Phase 3

51-75-2

4033

Palifosfamide

Investigational

Phase 3

31645-39-3

100427

Antineoplastic Agents, Immunological

Phase 2, Phase 3

Albumin-Bound Paclitaxel

Phase 2, Phase 3

Antimitotic Agents

Phase 2, Phase 3

Tubulin Modulators

Phase 2, Phase 3

Alkylating Agents

Phase 3

Antineoplastic Agents, Alkylating

Phase 3

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Aflibercept

Approved

Phase 2

862111-32-8

124490314

Thalidomide

Approved, Investigational, Withdrawn

Phase 2

50-35-1

5426

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239

Gemcitabine

Approved

Phase 2

95058-81-4, 122111-03-9

60750

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Lenvatinib

Approved, Investigational

Phase 2

417716-92-8

9823820

Atezolizumab

Approved, Investigational

Phase 2

1380723-44-3

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Rucaparib

Approved, Investigational

Phase 2

283173-50-2

9931954

Metformin

Approved

Phase 2

1115-70-4, 657-24-9

4091

Doxycycline

Approved, Investigational, Vet_approved

Phase 2

564-25-0

54671203

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Iniparib

Investigational

Phase 2

160003-66-7

9796068

Saracatinib

Investigational

Phase 2

379231-04-6

10302451

MK-1775

Investigational

Phase 2

955365-80-7

24856436

Spartalizumab

Investigational

Phase 2

1935694-88-4

Liver Extracts

Phase 2

Antimetabolites

Phase 2

Imatinib Mesylate

Phase 2

220127-57-1

Epothilones

Phase 2

Epothilone B

Phase 2

4456137

Protein Kinase Inhibitors

Phase 2

Poly(ADP-ribose) Polymerase Inhibitors

Phase 2

Angiogenesis Inhibitors

Phase 2

Immune Checkpoint Inhibitors

Phase 2

Antiprotozoal Agents

Phase 2

Antiparasitic Agents

Phase 2

Antimalarials

Phase 2

Hypoglycemic Agents

Phase 2

Immunoglobulins, Intravenous

Phase 2

Immunoglobulins

Phase 2

Immunoglobulin G

Phase 2

Interventional clinical trials:

(show all 32)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma	Recruiting	NCT05256225	Phase 2, Phase 3	Carboplatin;Hyaluronidase-zzxf/Pertuzumab/Trastuzumab;Paclitaxel;Trastuzumab/Hyaluronidase-oysk
2	A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary	Active, not recruiting	NCT00954174	Phase 3	Carboplatin;Ifosfamide;Paclitaxel
3	Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE)	Active, not recruiting	NCT03422198	Phase 3
4	A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma	Completed	NCT00687687	Phase 2	paclitaxel;carboplatin;BSI-201 (Iniparib)
5	A Phase II Evaluation of Paclitaxel (Taxol, NSC # 673089) and Carboplatin (Paraplatin, NSC #241240) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma	Completed	NCT00112489	Phase 2	carboplatin;paclitaxel
6	A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma	Completed	NCT00478426	Phase 2	Sunitinib Malate
7	A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma	Completed	NCT00659360	Phase 2	saracatinib
8	A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas	Completed	NCT00390234	Phase 2	ziv-aflibercept
9	A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus	Completed	NCT00025506	Phase 2	Thalidomide
10	A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma	Completed	NCT00238121	Phase 2	sorafenib tosylate
11	A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas	Completed	NCT00245102	Phase 2	sorafenib tosylate
12	A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer	Completed	NCT01010126	Phase 2	Temsirolimus
13	A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus	Completed	NCT00114218	Phase 2	Gemcitabine Hydrochloride;Docetaxel
14	A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus	Completed	NCT00075400	Phase 2	imatinib mesylate
15	A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus	Completed	NCT01247571	Phase 2	Pazopanib Hydrochloride
16	A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus	Completed	NCT01168232	Phase 2	Ixabepilone
17	A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas	Recruiting	NCT05147558	Phase 2	Pembrolizumab;Lenvatinib
18	A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma	Recruiting	NCT03668340	Phase 2	AZD1775
19	An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma	Active, not recruiting	NCT03694262	Phase 2	Rucaparib;Bevacizumab;Atezolizumab
20	Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff	Active, not recruiting	NCT04802876	Phase 2	Spartalizumab
21	A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer	Active, not recruiting	NCT01935934	Phase 2	Cabozantinib S-malate
22	A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer	Active, not recruiting	NCT02874430	Phase 2	Metformin Hydrochloride;Doxycycline
23	The EPOCH Study: Phase II Open Labelled Study Investigating the Use of Single Agent Eribulin and Eribulin in Combination With Pembrolizumab in Relapsed Tubo-ovarian or Uterine Carcinosarcoma	Not yet recruiting	NCT05619913	Phase 2	Eribulin Mesylate;Pembrolizumab
24	Pilot Phase II Study of Temsirolimus in Patients With Recurrent Mixed Mesodermal and Mullerian Tumors (Carcinosarcoma) of the Uterus	Terminated	NCT01061606	Phase 2	temsirolimus
25	A Dose Escalation Study of HFB301001 (OX40 Agonist Antibody) in Adult Patients With Advanced Solid Tumors	Recruiting	NCT05229601	Phase 1	HFB301001
26	Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)	Recruiting	NCT02020707	Phase 1	Nab-paclitaxel
27	Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb), in Patients With Metastatic or Recurrent Endometrial Cancer	Recruiting	NCT03120624	Phase 1	Ruxolitinib;Ruxolitinib Phosphate;Technetium Tc-99m Sodium Pertechnetate
28	Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Active, not recruiting	NCT03552471	Phase 1	Rucaparib Camsylate
29	A Pilot Investigation to Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in High-Risk Endometrial Cancers	Recruiting	NCT05049538
30	A Pilot Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Carcinosarcoma	Terminated	NCT01367301		paclitaxel;carboplatin
31	Pilot Study of Tislelizumab (BGB-A317) in Recurrent Mismatch Repair Deficient Endometrial Cancer and the Effect on the Tumor Microenvironment	Terminated	NCT04906382	Early Phase 1	Carboplatin;Paclitaxel
32	Web-Based Coping and Communication Skills Intervention for Women Who Are Newly Diagnosed With Gynecological Cancer: A Pilot Study	Withdrawn	NCT03902379

Search NIH Clinical Center for Uterine Carcinosarcoma

Sources

Genetic Tests for Uterine Carcinosarcoma

Sources

Anatomical Context for Uterine Carcinosarcoma

Organs/tissues related to Uterine Carcinosarcoma:

MalaCards : Uterus, Ovary, Breast, Endothelial, Liver, Lymph Node, Adrenal Gland

Sources

Publications for Uterine Carcinosarcoma

Articles related to Uterine Carcinosarcoma:

(show top 50) (show all 491)

#	Title	Authors	PMID	Year
1	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. ⁵	Chang MT...Taylor BS	26619011	2016
2	Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. ⁵³ ⁶²	Huh WK...Birrer MJ	20189232	2010
3	COX-2 expression in uterine carcinosarcoma. ⁵³ ⁶²	Menczer J...Levy T	19900134	2010
4	Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. ⁵³ ⁶²	Cimbaluk D...Bitterman P	17175012	2007
5	Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment? ⁵³ ⁶²	Raspollini MR...Taddei GL	16445668	2006
6	HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy. ⁵³ ⁶²	Raspollini MR...Taddei GL	15901136	2005
7	Cyclooxygenase-2 expression in uterine leiomyosarcomas. ⁵³ ⁶²	Raspollini MR...Taddei GL	15700850	2004
8	ERBB-2 gene overexpression and amplification in uterine sarcomas. ⁵³ ⁶²	Amant F...Vergote I	15581967	2004
9	Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. ⁵³ ⁶²	Sawada M...Matsubara O	14611676	2003
10	Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. ⁵³ ⁶²	Gorai I...Minaguchi H	9311600	1997
11	Improved survival with combination chemotherapy and external beam radiation therapy in uterine carcinosarcoma. ⁶²	McEachron J...Lee YC	36343971	2022
12	Feline uterine carcinosarcoma infiltrated with osteoclast-like giant cells. ⁶²	Murakami M...Sakai H	36261364	2022
13	Radical abdomino-pelvic surgery in the management of uterine carcinosarcoma with concomitant para-aortic lymphadenopathy metastasising from anal carcinoma. ⁶²	Cowdell I...Soleymani Majd H	36450419	2022
14	Identification of drug targets and prognosis projection for uterine carcinosarcoma based on alternative splicing events. ⁶²	Zhang X...Liang G	36470146	2022
15	Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types. ⁶²	Guo B...Zhang S	36255654	2022
16	Inter-component immunohistochemical assessment of proliferative markers in uterine carcinosarcoma. ⁶²	Pyra A...Semczuk A	36238851	2022
17	Incidence and survival rates of primary uterine carcinosarcoma in Korea: a National Cancer Registry study. ⁶²	Kim SI...Lim MC	36366811	2022
18	Management and Prognosis of Patients with Recurrent or Persistent/Progressive Uterine Carcinosarcoma. ⁶²	Tung HJ...Lai CH	36290878	2022
19	HER2 amplification in Uterine carcinosarcoma after tamoxifen therapy: a case report. ⁶²	Zheng F...Tian X	36149352	2022
20	Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: A systematic review and meta-analysis of survival. ⁶²	Raffone A...Mollo A	34797919	2022
21	cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma. ⁶²	Semiz HS...Sanci M	36178283	2022
22	Characterizing the extracellular matrix transcriptome of cervical, endometrial, and uterine cancers. ⁶²	Cook CJ...Fogg KC	35898192	2022
23	Clostridium and Bacteroides bacteremia as initial presentation of uterine carcinosarcoma. ⁶²	Imo CS...Lea JS	35866177	2022
24	Is minimally invasive surgery for clinical stage I uterine carcinosarcoma safe? ⁶²	Sinha R...Goldberg GL	34716874	2022
25	Prognostic value of the TCGA molecular classification in uterine carcinosarcoma. ⁶²	Travaglino A...Franco Zannoni G	34536971	2022
26	The role of multimodal adjuvant therapy for FIGO I-II carcinosarcoma of the uterus: a systematic review. ⁶²	van der Horst RL...Lalisang RI	35533817	2022
27	Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor. ⁶²	Tymon-Rosario JR...Santin AD	35599167	2022
28	Efficacy of pazopanib in FGFR1-amplified uterine carcinosarcoma: A case report. ⁶²	Sawayama S...Yamauchi C	35586703	2022
29	Evaluation of chemotherapy and radiotherapy in the adjuvant management of uterine carcinosarcoma: a population-based analysis. ⁶²	Ding L...Liu YM	35708782	2022
30	Role of Nucleolin in Endometrial Precancerous Hyperplasia and Carcinogenesis: Ex Vivo and In Silico Study. ⁶²	Barzilova VD...Hapangama DK	35682908	2022
31	Radiotherapy-induced uterine cacinosarcoma: A case report and review of the literature. ⁶²	Ahmed TB...Samouh N	35397302	2022
32	Sentinel lymph node biopsy alone compared to systematic lymphadenectomy in patients with uterine carcinosarcoma. ⁶²	Zammarrelli WA...Leitao MM	35232588	2022
33	Abandon ifosfamide-based regimen and use paclitaxel-carboplatin regimen for the treatment of uterine carcinosarcoma. ⁶²	Yang ST...Wang PH	35385437	2022
34	Uterine carcinosarcoma associated with a germline nibrin (NBN) mutation. ⁶²	Markert T...Konstantinopoulos PA	35434237	2022
35	Increasing incidence of uterine carcinosarcoma: A United States Cancer Statistics study. ⁶²	Liao CI...Chan JK	35169605	2022
36	HER2 Overexpression and Amplification in Uterine Carcinosarcomas With Serous Morphology. ⁶²	Jenkins TM...Mills AM	35125452	2022
37	Synchronous uterine and bladder cancers detected in urine and vaginal samples by cytology. ⁶²	Narine N...Crosbie EJ	34783454	2022
38	Evaluation of Saccharomyces cerevisiae-like 1 (SEC14L1) in Gynecologic Malignancies Shows Overexpression in Endometrial Serous Carcinoma. ⁶²	Banet N...Quddus MR	35283446	2022
39	Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. ⁶²	Powell MA...Miller DS	35007153	2022
40	Paclitaxel and Carboplatin for Uterine Carcinosarcoma: A Path to Inclusion. ⁶²	Roque DR...Matei D	35044808	2022
41	Response to anti-DKK1 therapy in uterine carcinosarcoma: A case report. ⁶²	ElNaggar A...Arend R	35531363	2022
42	Patterns of adjuvant treatment and survival outcomes in stage I uterine carcinosarcoma. ⁶²	Cory L...Ko EM	35111895	2022
43	Comparing paclitaxel-platinum with ifosfamide-platinum as the front-line chemotherapy for patients with advanced-stage uterine carcinosarcoma. ⁶²	Su MH...Wang PH	34698689	2022
44	Retrospective Analysis of Patients with Gynaecological Uterine Sarcomas in a Tertiary Hospital. ⁶²	Ruiz-Minaya M...De Leon-Luis JA	35207710	2022
45	Non-islet cell tumor hypoglycemia in a patient with uterine carcinosarcoma. ⁶²	Singleton MP...Clark LH	35005156	2022
46	How and where to expect endosalpingiosis intraoperatively. ⁶²	Burla L...Samartzis N	34986982	2022
47	Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis. ⁶²	Gao ZW...Dong K	35663977	2022
48	Exercise-induced IL-15 acted as a positive prognostic implication and tumor-suppressed role in pan-cancer. ⁶²	Luo Z...Chen S	36467072	2022
49	A transcriptome-Based Deep Neural Network Classifier for Identifying the Site of Origin in Mucinous Cancer. ⁶²	Ahn T...Lee K	36408331	2022
50	Clinicopathological Features Associated with Microsatellite Instability/Mismatch Repair Deficiency in Uterine Carcinosarcoma: A Quantitative Systematic Review. ⁶²	Travaglino A...Mollo A	35231921	2022

Sources

Genes for Uterine Carcinosarcoma

Genes related to Uterine Carcinosarcoma (0 elite genes):

(show all 36)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	TP53	Tumor Protein P53	Protein Coding	46.6	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)	26619011
2	PTEN	Phosphatase And Tensin Homolog	Protein Coding	46.18	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)	26619011
3	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	45.95	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)	26619011
4	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	45.82	Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	26619011 15901136 15589595 (more) 16445668 14611676 15581967 9311600 17175012
5	FBXW7	F-Box And WD Repeat Domain Containing 7	Protein Coding	45.77	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders Publications (show sections)	26619011
6	PPP2R1A	Protein Phosphatase 2 Scaffold Subunit Aalpha	Protein Coding	37.63	Likely pathogenic ⁵ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)	26619011
7	U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1	Protein Coding	31.63	Likely pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴	26619011
8	POLE	DNA Polymerase Epsilon, Catalytic Subunit	Protein Coding	31.05	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
9	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	30.64	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
10	PIK3R1	Phosphoinositide-3-Kinase Regulatory Subunit 1	Protein Coding	30.21	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
11	FGFR2	Fibroblast Growth Factor Receptor 2	Protein Coding	29.52	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
12	ERBB3	Erb-B2 Receptor Tyrosine Kinase 3	Protein Coding	29.28	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
13	LRRC56	Leucine Rich Repeat Containing 56	Protein Coding	25	Likely pathogenic ⁵	26619011
14	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	19.9	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15589595 14611676 20189232 (more) 17175012
15	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	16.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15589595 19900134 11605037 (more) 15700850
16	EGFR	Epidermal Growth Factor Receptor	Protein Coding	12.72	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
17	VIM	Vimentin	Protein Coding	11.03	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
18	CHD4	Chromodomain Helicase DNA Binding Protein 4	Protein Coding	10.71	DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)
19	KRT8	Keratin 8	Protein Coding	10.31	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
20	H2AC18	H2A Clustered Histone 18	Protein Coding	7.12	DISEASES inferred ¹⁴ ¹⁴
21	MB	Myoglobin	Protein Coding	6.97	GeneCards inferred via : Publications (show sections)
22	SLC25A16	Solute Carrier Family 25 Member 16	Protein Coding	6.29	DISEASES inferred ¹⁴
23	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	6.03	DISEASES inferred ¹⁴ ¹⁴
24	ARID1A	AT-Rich Interaction Domain 1A	Protein Coding	5.9	DISEASES inferred ¹⁴
25	CD274	CD274 Molecule	Protein Coding	5.7	DISEASES inferred ¹⁴
26	CD8A	CD8a Molecule	Protein Coding	5.57	DISEASES inferred ¹⁴
27	MSH2	MutS Homolog 2	Protein Coding	5.55	DISEASES inferred ¹⁴
28	MLH1	MutL Homolog 1	Protein Coding	5.54	DISEASES inferred ¹⁴
29	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	5.51	DISEASES inferred ¹⁴
30	MSH6	MutS Homolog 6	Protein Coding	5.5	DISEASES inferred ¹⁴
31	CTNNB1	Catenin Beta 1	Protein Coding	5.48	DISEASES inferred ¹⁴
32	PMS2	PMS1 Homolog 2, Mismatch Repair System Component	Protein Coding	5.42	DISEASES inferred ¹⁴
33	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	5.36	DISEASES inferred ¹⁴
34	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	5.28	DISEASES inferred ¹⁴
35	RACGAP1	Rac GTPase Activating Protein 1	Protein Coding	5.28	DISEASES inferred ¹⁴
36	ESR1	Estrogen Receptor 1	Protein Coding	5.27	DISEASES inferred ¹⁴

Sources

Variations for Uterine Carcinosarcoma

ClinVar genetic disease variations for Uterine Carcinosarcoma:

⁵ (show top 50) (show all 174)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	PIK3CA	NM_006218.4(PIK3CA):c.316G>C (p.Gly106Arg)	SNV	Likely Pathogenic	376480	rs1057519931	GRCh37: 3:178916929-178916929 GRCh38: 3:179199141-179199141
2	FBXW7	NM_001349798.2(FBXW7):c.1973G>A (p.Arg658Gln)	SNV	Likely Pathogenic	376427	rs759610249	GRCh37: 4:153244184-153244184 GRCh38: 4:152323032-152323032
3	PPP2R1A	NM_014225.6(PPP2R1A):c.536C>G (p.Pro179Arg)	SNV	Likely Pathogenic	376504	rs786205228	GRCh37: 19:52715971-52715971 GRCh38: 19:52212718-52212718
4	POLE	NM_006231.4(POLE):c.856C>T (p.Pro286Ser)	SNV	Likely Pathogenic	376501	rs1057519944	GRCh37: 12:133253185-133253185 GRCh38: 12:132676599-132676599
5	POLE	NM_006231.4(POLE):c.857C>A (p.Pro286His)	SNV	Likely Pathogenic	376502	rs1057519943	GRCh37: 12:133253184-133253184 GRCh38: 12:132676598-132676598
6	PIK3R1	NM_181523.3(PIK3R1):c.1126G>C (p.Gly376Arg)	SNV	Likely Pathogenic	376065	rs1057519757	GRCh37: 5:67589138-67589138 GRCh38: 5:68293310-68293310
7	PPP2R1A	NM_014225.6(PPP2R1A):c.536C>T (p.Pro179Leu)	SNV	Likely Pathogenic	190313	rs786205228	GRCh37: 19:52715971-52715971 GRCh38: 19:52212718-52212718
8	PIK3CA	NM_006218.4(PIK3CA):c.317G>T (p.Gly106Val)	SNV	Likely Pathogenic	376479	rs1057519930	GRCh37: 3:178916930-178916930 GRCh38: 3:179199142-179199142
9	ERBB3	NM_001982.4(ERBB3):c.889G>A (p.Asp297Asn)	SNV	Likely Pathogenic	376409	rs1057519891	GRCh37: 12:56482341-56482341 GRCh38: 12:56088557-56088557
10	FBXW7	NM_001349798.2(FBXW7):c.1513C>A (p.Arg505Ser)	SNV	Likely Pathogenic	376426	rs149680468	GRCh37: 4:153247289-153247289 GRCh38: 4:152326137-152326137
11	PPP2R1A	NM_014225.6(PPP2R1A):c.548G>A (p.Arg183Gln)	SNV	Likely Pathogenic	376506	rs1057519947	GRCh37: 19:52715983-52715983 GRCh38: 19:52212730-52212730
12	FBXW7	NM_001349798.2(FBXW7):c.1513C>G (p.Arg505Gly)	SNV	Likely Pathogenic	376423	rs149680468	GRCh37: 4:153247289-153247289 GRCh38: 4:152326137-152326137
13	FBXW7	NM_001349798.2(FBXW7):c.1435C>G (p.Arg479Gly)	SNV	Likely Pathogenic	376422	rs747241612	GRCh37: 4:153247367-153247367 GRCh38: 4:152326215-152326215
14	ERBB2	NM_004448.4(ERBB2):c.2524G>A (p.Val842Ile)	SNV	Likely Pathogenic	375994	rs1057519738	GRCh37: 17:37881332-37881332 GRCh38: 17:39725079-39725079
15	ERBB3	NM_001982.4(ERBB3):c.310G>A (p.Val104Met)	SNV	Likely Pathogenic	376410	rs1057519893	GRCh37: 12:56478854-56478854 GRCh38: 12:56085070-56085070
16	PPP2R1A	NM_014225.6(PPP2R1A):c.547C>T (p.Arg183Trp)	SNV	Likely Pathogenic	376505	rs1057519946	GRCh37: 19:52715982-52715982 GRCh38: 19:52212729-52212729
17	PPP2R1A	NM_014225.6(PPP2R1A):c.547C>G (p.Arg183Gly)	SNV	Likely Pathogenic	376507	rs1057519946	GRCh37: 19:52715982-52715982 GRCh38: 19:52212729-52212729
18	PIK3CA	NM_006218.4(PIK3CA):c.1034A>C (p.Asn345Thr)	SNV	Likely Pathogenic	376489	rs1057519938	GRCh37: 3:178921552-178921552 GRCh38: 3:179203764-179203764
19	FBXW7	NM_001349798.2(FBXW7):c.1514G>T (p.Arg505Leu)	SNV	Likely Pathogenic	376424	rs1057519896	GRCh37: 4:153247288-153247288 GRCh38: 4:152326136-152326136
20	FBXW7	NM_001349798.2(FBXW7):c.1513C>T (p.Arg505Cys)	SNV	Likely Pathogenic	69961	rs149680468	GRCh37: 4:153247289-153247289 GRCh38: 4:152326137-152326137
21	FBXW7	NM_001349798.2(FBXW7):c.1436G>C (p.Arg479Pro)	SNV	Likely Pathogenic	376420	rs866987936	GRCh37: 4:153247366-153247366 GRCh38: 4:152326214-152326214
22	PIK3CA	NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)	SNV	Likely Pathogenic	13659	rs121913274	GRCh37: 3:178936092-178936092 GRCh38: 3:179218304-179218304
23	PIK3CA	NM_006218.4(PIK3CA):c.1034A>T (p.Asn345Ile)	SNV	Likely Pathogenic	376488	rs1057519938	GRCh37: 3:178921552-178921552 GRCh38: 3:179203764-179203764
24	PIK3CA	NM_006218.4(PIK3CA):c.1634A>G (p.Glu545Gly)	SNV	Likely Pathogenic	13656	rs121913274	GRCh37: 3:178936092-178936092 GRCh38: 3:179218304-179218304
25	U2AF1	NM_006758.3(U2AF1):c.101C>A (p.Ser34Tyr)	SNV	Likely Pathogenic	376026	rs371769427	GRCh37: 21:44524456-44524456 GRCh38: 21:43104346-43104346
26	ERBB3	NM_001982.4(ERBB3):c.310G>T (p.Val104Leu)	SNV	Likely Pathogenic	376411	rs1057519893	GRCh37: 12:56478854-56478854 GRCh38: 12:56085070-56085070
27	PIK3CA	NM_006218.4(PIK3CA):c.1633G>C (p.Glu545Gln)	SNV	Likely Pathogenic	375896	rs104886003	GRCh37: 3:178936091-178936091 GRCh38: 3:179218303-179218303
28	U2AF1	NM_006758.3(U2AF1):c.101C>T (p.Ser34Phe)	SNV	Likely Pathogenic	376025	rs371769427	GRCh37: 21:44524456-44524456 GRCh38: 21:43104346-43104346
29	FBXW7	NM_001349798.2(FBXW7):c.1514G>A (p.Arg505His)	SNV	Likely Pathogenic	376425	rs1057519896	GRCh37: 4:153247288-153247288 GRCh38: 4:152326136-152326136
30	ERBB3	NM_001982.4(ERBB3):c.890A>T (p.Asp297Val)	SNV	Likely Pathogenic	376408	rs1057519892	GRCh37: 12:56482342-56482342 GRCh38: 12:56088558-56088558
31	FBXW7	NM_001349798.2(FBXW7):c.1436G>T (p.Arg479Leu)	SNV	Likely Pathogenic	376421	rs866987936	GRCh37: 4:153247366-153247366 GRCh38: 4:152326214-152326214
32	PIK3CA	NM_006218.4(PIK3CA):c.263G>A (p.Arg88Gln)	SNV	Likely Pathogenic	376049	rs121913287	GRCh37: 3:178916876-178916876 GRCh38: 3:179199088-179199088
33	PIK3CA	NM_006218.4(PIK3CA):c.1033A>C (p.Asn345His)	SNV	Likely Pathogenic	376490	rs1057519939	GRCh37: 3:178921551-178921551 GRCh38: 3:179203763-179203763
34	ERBB3	NM_001982.4(ERBB3):c.889G>T (p.Asp297Tyr)	SNV	Likely Pathogenic	376407	rs1057519891	GRCh37: 12:56482341-56482341 GRCh38: 12:56088557-56088557
35	FBXW7	NM_001349798.2(FBXW7):c.1436G>A (p.Arg479Gln)	SNV	Likely Pathogenic	376419	rs866987936	GRCh37: 4:153247366-153247366 GRCh38: 4:152326214-152326214
36	FBXW7	NM_001349798.2(FBXW7):c.1394G>C (p.Arg465Pro)	SNV	Likely Pathogenic	376416	rs1057519895	GRCh37: 4:153249384-153249384 GRCh38: 4:152328232-152328232
37	FBXW7	NM_001349798.2(FBXW7):c.1394G>T (p.Arg465Leu)	SNV	Likely Pathogenic	376417	rs1057519895	GRCh37: 4:153249384-153249384 GRCh38: 4:152328232-152328232
38	PIK3CA	NM_006218.4(PIK3CA):c.1637A>T (p.Gln546Leu)	SNV	Likely Pathogenic	375899	rs397517201	GRCh37: 3:178936095-178936095 GRCh38: 3:179218307-179218307
39	PIK3CA	NM_006218.4(PIK3CA):c.1635G>T (p.Glu545Asp)	SNV	Likely Pathogenic	217293	rs121913275	GRCh37: 3:178936093-178936093 GRCh38: 3:179218305-179218305
40	PIK3CA	NM_006218.4(PIK3CA):c.1637A>G (p.Gln546Arg)	SNV	Likely Pathogenic	45466	rs397517201	GRCh37: 3:178936095-178936095 GRCh38: 3:179218307-179218307
41	PIK3CA	NM_006218.4(PIK3CA):c.1636C>G (p.Gln546Glu)	SNV	Likely Pathogenic	13654	rs121913286	GRCh37: 3:178936094-178936094 GRCh38: 3:179218306-179218306
42	FBXW7	NM_001349798.2(FBXW7):c.1394G>A (p.Arg465His)	SNV	Likely Pathogenic	376415	rs1057519895	GRCh37: 4:153249384-153249384 GRCh38: 4:152328232-152328232
43	FBXW7	NM_001349798.2(FBXW7):c.1393C>T (p.Arg465Cys)	SNV	Likely Pathogenic	376414	rs867384286	GRCh37: 4:153249385-153249385 GRCh38: 4:152328233-152328233
44	PIK3CA	NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)	SNV	Likely Pathogenic	13653	rs121913279	GRCh37: 3:178952085-178952085 GRCh38: 3:179234297-179234297
45	PIK3CA	NM_006218.4(PIK3CA):c.1637A>C (p.Gln546Pro)	SNV	Likely Pathogenic	375898	rs397517201	GRCh37: 3:178936095-178936095 GRCh38: 3:179218307-179218307
46	PIK3CA	NM_006218.4(PIK3CA):c.1636C>A (p.Gln546Lys)	SNV	Likely Pathogenic	13657	rs121913286	GRCh37: 3:178936094-178936094 GRCh38: 3:179218306-179218306
47	FBXW7	NM_001349798.2(FBXW7):c.1393C>G (p.Arg465Gly)	SNV	Likely Pathogenic	376418	rs867384286	GRCh37: 4:153249385-153249385 GRCh38: 4:152328233-152328233
48	PIK3CA	NM_006218.4(PIK3CA):c.1638G>T (p.Gln546His)	SNV	Likely Pathogenic	376491	rs1057519940	GRCh37: 3:178936096-178936096 GRCh38: 3:179218308-179218308
49	PIK3CA	NM_006218.4(PIK3CA):c.3141T>G (p.His1047Gln)	SNV	Likely Pathogenic	376481	rs1057519932	GRCh37: 3:178952086-178952086 GRCh38: 3:179234298-179234298
50	PIK3CA	NM_006218.4(PIK3CA):c.1035T>A (p.Asn345Lys)	SNV	Likely Pathogenic	376050	rs121913284	GRCh37: 3:178921553-178921553 GRCh38: 3:179203765-179203765

Sources

Expression for Uterine Carcinosarcoma

Search GEO for disease gene expression data for Uterine Carcinosarcoma.

Sources

Pathways for Uterine Carcinosarcoma

Pathways related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 128)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.92	VIM TP53 PTGS2 PTEN PPP2R1A PIK3R1
2	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.84	CHD4 EGFR ERBB2 ERBB3 FBXW7 FGFR2
3	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.8	EGFR ERBB2 ERBB3 FGFR2 HRAS KIT
4	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.73	TP53 PTGS2 PPP2R1A PIK3R1 KIT HRAS
5	Signal Transduction ⁶⁶	13.72	VIM TP53 PTEN PPP2R1A PIK3R1 PIK3CA
6	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.64	TP53 PPP2R1A PIK3R1 PIK3CA KIT HRAS
7	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.57	TP53 PTEN PIK3R1 PIK3CA HRAS FGFR2
8	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.52	TP53 PTEN PPP2R1A PIK3R1 KIT HRAS
9	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.47	EGFR ERBB2 ERBB3 FBXW7 FGFR2 HRAS
10	CREB Pathway ⁶⁴ Show member pathways Activation of PKC through GPCR ⁶⁴ Intracellular Calcium Signaling ⁶⁴ IP3 Pathway ⁶⁴	13.42	EGFR ERBB2 ERBB3 FGFR2 HRAS KIT
11	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.41	VIM TP53 PTGS2 PPP2R1A PIK3R1 PIK3CA
12	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.39	PTEN PIK3R1 KIT HRAS FGFR2 ERBB2
13	Nanog in Mammalian ESC Pluripotency ⁶⁴ Show member pathways 14-3-3 Induced Intracellular Signaling ⁶⁴ eNOS Signaling ⁶⁴ GSK3 Signaling ⁶⁴	13.39	VIM PPP2R1A PIK3R1 KIT HRAS FGFR2
14	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	13.17	TP53 PTEN PIK3R1 KIT HRAS FGFR2
15	p70S6K Signaling ⁶⁴ Show member pathways mTOR Pathway ⁶⁴ Renin-Angiotensin Pathway ⁶⁴	13.16	EGFR FGFR2 HRAS KIT PIK3R1 PPP2R1A
16	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	13.06	EGFR FGFR2 HRAS KIT PIK3CA PIK3R1
17	PIP3 activates AKT signaling ⁶⁶ Show member pathways Intracellular signaling by second messengers ⁶⁶ PTEN Regulation ⁶⁶ Regulation of PTEN gene transcription ⁶⁶ Regulation of PTEN localization ⁶⁶	13.04	CHD4 EGFR ERBB2 ERBB3 FGFR2 KIT
18	Actin Nucleation by ARP-WASP Complex ⁶⁴ Show member pathways Actin Nucleation and Branching ⁶⁴ CDC42 Pathway ⁶⁴ RhoA Pathway ⁶⁴	13.03	KIT FGFR2 ERBB3 ERBB2 EGFR
19	TNFR1 Pathway ⁶⁴ Show member pathways Apoptosis ⁷⁴ Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis modulation by HSP70 ⁷⁴ Apoptosis through Death Receptors ⁶⁴ Apoptotic Pathways Triggered By HIV1 ⁶⁴ Ceramide signaling pathway ⁶¹ DR3 Signaling ⁶⁴ GITR Pathway ⁶⁴ HIV-1 Nef: Negative effector of Fas and TNF-alpha ⁶¹ Stimulation of the cell death response by PAK-2p34 ⁶⁶ TNF Signaling ⁶⁴ TNF-related weak inducer of apoptosis (TWEAK) signaling pathway ⁷⁴ TRAIL Pathway ⁶⁴ TWEAK Pathway ⁶⁴	13.01	TP53 PTEN PIK3R1 PIK3CA HRAS EGFR
20	NFAT and Cardiac Hypertrophy ⁶⁴ Show member pathways IGF1R Signaling ⁶⁴ Signaling Involved in Cardiac Hypertrophy ⁶⁴	12.99	EGFR ERBB2 ERBB3 FGFR2 HRAS PIK3CA
21	Development Angiotensin activation of ERK ²² Show member pathways Cell adhesion Integrin inside-out signaling ²² Development ACM2 and ACM4 activation of ERK ²² Development Angiotensin signaling via PYK2 ²² Development EDNRB signaling ²² Development EPO-induced MAPK pathway ²² Development G-Proteins mediated regulation MARK-ERK signaling ²² Signal transduction IP3 signaling ²²	12.93	PIK3R1 PIK3CA KIT HRAS EGFR
22	Translation Insulin regulation of translation ²² Show member pathways Butyrate-induced histone acetylation ⁷⁴ Cell adhesion PLAU signaling ²² Development CNTF receptor signaling ²² Development Growth hormone signaling via PI3K/AKT and MAPK cascades ²² Overview of perturbations to host-cell autophagy, induced by distinct proteins of SARS-CoV-2 ⁷⁴ Regulation of lipid metabolism Insulin signaling-generic cascades ²² Transcription Receptor-mediated HIF regulation ²² Translation Regulation of EIF2 activity ²² Translation Regulation of EIF4F activity ²² Translation inhibitors in chronically activated PDGFRA cells ⁷⁴	12.83	EGFR HRAS PIK3CA PIK3R1 PTEN
23	Malignant pleural mesothelioma ⁷⁴	12.83	TP53 PTEN PIK3CA KIT HRAS FGFR2
24	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.79	PPP2R1A PIK3R1 PIK3CA KIT HRAS FGFR2
25	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.76	TP53 PPP2R1A PIK3R1 HRAS EGFR
26	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.76	TP53 PPP2R1A PIK3R1 PIK3CA KIT HRAS
27	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.72	EGFR ERBB2 HRAS PIK3CA PIK3R1 TP53
28	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ⁶⁶ Show member pathways Constitutive Signaling by Aberrant PI3K in Cancer ⁶⁶ Negative regulation of the PI3K/AKT network ⁶⁶ PI3K/AKT Signaling in Cancer ⁶⁶	12.71	EGFR ERBB2 ERBB3 FGFR2 KIT PIK3CA
29	Negative regulation of FGFR1 signaling ⁶⁶ Show member pathways FGFR1 ligand binding and activation ⁶⁶ FGFR1b ligand binding and activation ⁶⁶ FGFR1c and Klotho ligand binding and activation ⁶⁶ FGFR1c ligand binding and activation ⁶⁶ FGFRL1 modulation of FGFR1 signaling ⁶⁶ Negative regulation of FGFR2 signaling ⁶⁶ Negative regulation of FGFR3 signaling ⁶⁶ Negative regulation of FGFR4 signaling ⁶⁶ Signaling by activated point mutants of FGFR1 ⁶⁶ Signaling by FGFR1 ⁶⁶ Signaling by FGFR1 amplification mutants ⁶⁶ Signaling by FGFR3 ⁶⁶ Signaling by FGFR4 ⁶⁶ Spry regulation of FGF signaling ⁶⁶	12.69	PPP2R1A PIK3R1 PIK3CA HRAS FGFR2
30	Signaling by NTRKs ⁶⁶ Show member pathways Activated NTRK3 signals through PI3K ⁶⁶ Activated NTRK3 signals through PLCG1 ⁶⁶ Activated NTRK3 signals through RAS ⁶⁶ Activation of TRKA receptors ⁶⁶ NGF-independant TRKA activation ⁶⁶ NTF3 activates NTRK3 signaling ⁶⁶ NTRK3 as a dependence receptor ⁶⁶ PI3K/AKT activation ⁶⁶ Retrograde neurotrophin signalling ⁶⁶ Signaling by NTRK1 (TRKA) ⁶⁶ Signaling by NTRK3 (TRKC) ⁶⁶	12.66	PPP2R1A PIK3R1 PIK3CA HRAS CHD4
31	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.62	EGFR ERBB2 ERBB3 HRAS PIK3CA PIK3R1
32	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.56	TP53 PTGS2 PTEN PIK3R1 PIK3CA HRAS
33	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.53	EGFR ERBB2 ERBB3 FGFR2 HRAS PIK3CA
34	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.52	EGFR ERBB2 ERBB3 FGFR2 HRAS KIT
35	Development FGFR signaling pathway ²² Show member pathways Development FGF-family signaling ²² Development Flt3 signaling ²² FGF Pathway ⁶⁴	12.5	PIK3R1 PIK3CA HRAS FGFR2
36	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.49	PIK3R1 PIK3CA HRAS EGFR
37	RhoGDI Pathway ⁶⁴ Show member pathways Fc-GammaR-Mediated Phagocytosis in Macrophages ⁶⁴	12.48	EGFR FGFR2 HRAS PIK3R1
38	MAPK signaling pathway ⁷⁴	12.48	TP53 HRAS FGFR2 EGFR
39	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.48	PTGS2 PIK3R1 PIK3CA HRAS
40	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.44	TP53 PTGS2 PIK3R1 PIK3CA HRAS
41	Focal adhesion ⁷⁴	12.43	PTEN PIK3R1 PIK3CA HRAS ERBB2 EGFR
42	Immune response Fc epsilon RI pathway ²² Show member pathways Fc-epsilon receptor I signaling in mast cells ⁶¹ Immune response BCR pathway ²²	12.42	PTEN PIK3R1 PIK3CA HRAS
43	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.42	EGFR ERBB2 ERBB3 HRAS PIK3CA PIK3R1
44	B Cell Receptor Signaling Pathway ⁶⁷ Show member pathways T Cell Receptor Signaling Pathway ⁶⁷	12.41	PTEN PIK3R1 PIK3CA HRAS
45	PDGFR-beta signaling pathway ⁶¹ Show member pathways ErbB1 downstream signaling ⁶¹	12.4	PTEN PPP2R1A PIK3R1 PIK3CA EGFR
46	Signaling by FGFR2 ⁶⁶ Show member pathways FGFR2 ligand binding and activation ⁶⁶ FGFR2b ligand binding and activation ⁶⁶ Signaling by FGFR ⁶⁶	12.39	PPP2R1A PIK3R1 PIK3CA HRAS FGFR2
47	Development IGF-1 receptor signaling ²² Show member pathways Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.38	TP53 PTEN PIK3R1 PIK3CA HRAS
48	Ras signaling ⁷⁴	12.38	PIK3R1 PIK3CA KIT HRAS FGFR2 EGFR
49	Signaling by ERBB2 KD Mutants ⁶⁶ Show member pathways Constitutive Signaling by Overexpressed ERBB2 ⁶⁶ GRB2 events in ERBB2 signaling ⁶⁶ PI3K events in ERBB2 signaling ⁶⁶ PI3K events in ERBB4 signaling ⁶⁶ PLCG1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB4 signaling ⁶⁶ Signaling by ERBB2 ECD mutants ⁶⁶ Signaling by ERBB2 in Cancer ⁶⁶ Signaling by ERBB2 TMD/JMD mutants ⁶⁶	12.37	PIK3R1 PIK3CA HRAS ERBB3 ERBB2 EGFR
50	Development Endothelin-1/EDNRA transactivation of EGFR ²² Show member pathways Cytoskeleton remodeling FAK signaling ²² Development Endothelin-1/EDNRA signaling ²²	12.35	PIK3R1 PIK3CA HRAS EGFR

Sources

GO Terms for Uterine Carcinosarcoma

Cellular components related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	receptor complex	GO:0043235	9.96	KIT FGFR2 ERBB3 ERBB2 EGFR
2	ERBB3:ERBB2 complex	GO:0038143	9.46	ERBB3 ERBB2
3	plasma membrane region	GO:0098590	9.13	ERBB3 ERBB2 EGFR
4	obsolete spanning component of plasma membrane	GO:0044214	8.8	ERBB3 ERBB2 EGFR

Biological processes related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 15)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of ERK1 and ERK2 cascade	GO:0070374	10.22	PTEN HRAS FGFR2 FBXW7 EGFR
2	negative regulation of apoptotic process	GO:0043066	10.22	TP53 PTGS2 PTEN PIK3R1 ERBB3 ERBB2
3	positive regulation of cell population proliferation	GO:0008284	10.17	PTGS2 PTEN KIT HRAS FGFR2 ERBB3
4	positive regulation of MAP kinase activity	GO:0043406	10.1	EGFR ERBB2 HRAS KIT
5	transmembrane receptor protein tyrosine kinase signaling pathway	GO:0007169	10.1	EGFR ERBB2 ERBB3 FGFR2 KIT
6	peptidyl-tyrosine phosphorylation	GO:0018108	10.09	KIT FGFR2 ERBB3 ERBB2 EGFR
7	positive regulation of epithelial cell proliferation	GO:0050679	10.06	HRAS FGFR2 ERBB2 EGFR
8	embryonic organ development	GO:0048568	10.02	TP53 POLE FGFR2
9	regulation of ERK1 and ERK2 cascade	GO:0070372	9.99	FGFR2 ERBB2 EGFR
10	phosphorylation	GO:0016310	9.97	PIK3R1 PIK3CA KIT FGFR2 ERBB3 ERBB2
11	positive regulation of kinase activity	GO:0033674	9.96	EGFR ERBB2 ERBB3 FGFR2 KIT
12	ERBB2-ERBB3 signaling pathway	GO:0038133	9.84	ERBB3 ERBB2
13	phosphatidylinositol 3-kinase signaling	GO:0014065	9.65	PTEN PIK3R1 PIK3CA ERBB3 ERBB2
14	multicellular organism development	GO:0007275	9.55	KIT FGFR2 ERBB3 ERBB2 EGFR
15	regulation of cell population proliferation	GO:0042127	9.32	TP53 PTGS2 KIT HRAS ERBB3 ERBB2

Molecular functions related to Uterine Carcinosarcoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein heterodimerization activity	GO:0046982	10.15	TP53 PPP2R1A PIK3R1 H2AC18 ERBB3 ERBB2
2	nucleotide binding	GO:0000166	10.02	POLE PIK3CA KIT HRAS FGFR2 ERBB3
3	protein phosphatase binding	GO:0019903	10.01	TP53 PIK3R1 ERBB2 EGFR
4	protein tyrosine kinase activity	GO:0004713	9.96	EGFR ERBB2 ERBB3 FGFR2 KIT
5	kinase activity	GO:0016301	9.76	PIK3R1 PIK3CA KIT FGFR2 ERBB3 ERBB2
6	ErbB-3 class receptor binding	GO:0043125	9.43	PIK3R1 ERBB3 ERBB2
7	transmembrane receptor protein tyrosine kinase activity	GO:0004714	9.28	KIT FGFR2 ERBB3 ERBB2 EGFR